Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AUROVELA 24 FE vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Prevention of pregnancy,Treatment of heavy menstrual bleeding (off-label),Treatment of dysmenorrhea (off-label),Acne vulgaris (off-label)
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days.
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Primarily metabolized via CYP3A4. Norethindrone undergoes reduction and conjugation; ethinyl estradiol undergoes phase I (hydroxylation via CYP3A4) and phase II (glucuronidation) metabolism.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates.
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
Norethindrone: ~91% to albumin and SHBG; Ethinyl estradiol: ~97% to albumin.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
Norethindrone: ~1.5 L/kg; Ethinyl estradiol: ~15 L/kg. Indicates extensive tissue distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Norethindrone: ~64%; Ethinyl estradiol: ~43% (oral).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment required for mild to moderate renal impairment. Use is not recommended in severe renal impairment or acute renal failure due to potential accumulation of components.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
Contraindicated in patients with hepatic impairment or active liver disease. No specific dose adjustments provided for mild impairment; use not recommended in Child-Pugh class B or C.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Safety and efficacy established in females of reproductive age post-menarche. Dosing same as adults (0.10 mg/1.0 mg daily for 24 days, then placebo for 4 days).
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
Not indicated for use in postmenopausal women. No specific dose adjustments required for elderly, but consider risks of thromboembolism and other comorbidities.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, stroke, MI),Hepatic neoplasia,Gallbladder disease,Hypertension,Hyperkalemia in renal impairment (due to drospirenone component in some formulations; not applicable to this product),Glucose intolerance,Depression,Uterine bleeding irregularities,Follicular atresia and amenorrhea after discontinuation,Contact lens intolerance
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Thrombophlebitis or thromboembolic disorders,History of DVT or PE,Cerebrovascular or coronary artery disease,Known or suspected pregnancy,Undiagnosed abnormal vaginal bleeding,Known or suspected breast cancer,Carcinoma of endometrium or other estrogen-dependent neoplasia,Hepatic adenoma or carcinoma,Active liver disease with impaired function,Hypersensitivity to any component,Smoking in women over 35
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No food interactions documented. Grapefruit juice may increase estrogen exposure but not clinically significant; no restriction needed.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and potential for neonatal hepatic dysfunction. Contraindicated in pregnancy due to teratogenicity.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Excreted in breast milk in low amounts; M/P ratio not well established. Use during lactation is generally not recommended due to potential adverse effects on infant, including jaundice and hormonal changes. May suppress milk production.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
Not applicable; use is contraindicated during pregnancy. No dose adjustment can mitigate fetal risk; immediate discontinuation upon confirmed pregnancy is required.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
AUROVELA 24 FE is a combined oral contraceptive containing norethindrone acetate and ethinyl estradiol with ferrous fumarate placebo. The iron supplement in placebo pills is not bioavailable and does not treat iron deficiency. Counsel that withdrawal bleed typically occurs during the 4th week (iron pills). Missed pills algorithm: if one active pill missed, take as soon as remembered; if two or more missed, take last missed and use backup contraception for 7 days. Induction of CYP3A4 by rifampin, anticonvulsants, St. John's wort may reduce efficacy. Do not prescribe with concomitant hepatitis C therapy containing ombitasvir/paritaprevir/ritonavir due to ALT elevations.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time, preferably after the evening meal to reduce nausea.,The last 7 tablets are brown iron pills; you will have a withdrawal bleed during this time.,If you vomit within 4 hours of taking an active pill, take another active pill from a separate pack.,Missing two or more active pills may require backup contraception (condoms) for 7 days.,Smoking increases risk of serious cardiovascular side effects; avoid smoking while on this medication.,Report any symptoms of blood clots: sudden leg pain/swelling, chest pain, shortness of breath, severe headache, vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature away from moisture and heat.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AUROVELA 24 FE vs ALTAVERA, answered by our medical review team.
AUROVELA 24 FE is a Oral Contraceptive that works by Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AUROVELA 24 FE and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AUROVELA 24 FE is: One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AUROVELA 24 FE and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AUROVELA 24 FE is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects and cardiovascular anomalies. Second/third trimester: Risk of fetal genital abnormalities and poten. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.